- Details
- Description
-
Packaging Size7t*2blister/Box
-
Strength150mg
-
CompositonSunvozertinib
-
Treatmentadult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations
-
FormTablet
-
Brand舒沃哲®
-
Quantity Unit14t/Box
-
ManufacturerDizal Pharma, china
Sunvozertinib (DZD9008) is an oral, potent, irreversible, and selective EGFR TKI targeting EGFR exon20ins as well as EGFR sensitizing, T790M, and uncommon mutations with weak activity against wild-type EGFR.
Sunvozertinib is being developed by Dizal Pharmaceuticals, a joint venture between AstraZeneca and the Chinese Future Industry Investment Fund.
- Sunvozertinib sold under the brand name 舒沃哲® in china.
In August 2023, China’s National Medical Products Administration approved sunvozertinib for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease has progressed on or following platinum-based chemotherapy, based on data from the phase 2 WU-KONG6 trial (NCT05712902).
